AR125407A2 - Procedimiento para la preparación de partículas de polímero farmacéuticas y/o cosméticas, y procedimiento para la preparación de composiciones farmacéuticas y/o cosméticas que comprenden dichas partículas - Google Patents

Procedimiento para la preparación de partículas de polímero farmacéuticas y/o cosméticas, y procedimiento para la preparación de composiciones farmacéuticas y/o cosméticas que comprenden dichas partículas

Info

Publication number
AR125407A2
AR125407A2 ARP220101046A ARP220101046A AR125407A2 AR 125407 A2 AR125407 A2 AR 125407A2 AR P220101046 A ARP220101046 A AR P220101046A AR P220101046 A ARP220101046 A AR P220101046A AR 125407 A2 AR125407 A2 AR 125407A2
Authority
AR
Argentina
Prior art keywords
lactic
poly
plga
glycolic acid
pharmaceutical
Prior art date
Application number
ARP220101046A
Other languages
English (en)
Inventor
Yannis Guillemin
Dominique Vacher
Thomas Perrier
Maud Gonnet
Jean-Nol Gouze
Original Assignee
Ibsa Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ibsa Pharma Sas filed Critical Ibsa Pharma Sas
Publication of AR125407A2 publication Critical patent/AR125407A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Procedimiento para la preparación de partículas de polímero farmacéuticas y/o cosméticas compuestas por al menos un copolímero de poli(ácido láctico-co-glicólico)-polietilenglicol-poli(ácido láctico-co-glicólico) (PLGA-PEG-PLGA), o una mezcla de polímero de poli(ácido láctico-co-glicólico) (PLGA) y copolímero de poli(ácido láctico-co-glicólico)-polietilenglicol-poli(ácido láctico-co-glicólico) (PLGA-PEG-PLGA), donde la proporción en peso del polímero poli(ácido láctico-co-glicólico) (PLGA) al copolímero de poli(ácido láctico-co-glicólico)-polietilenglicol-poli(ácido láctico-co-glicólico) (PLGA-PEG-PLGA) varía de 40/60 a 60/40, combinado con moléculas de ácido hialurónico o sales de ácido hialurónico, que comprende las etapas siguientes: (iv) con agitación, emulsionar una solución acuosa de ácido hialurónico o de sales de ácido hialurónico en una solución orgánica que comprende al menos un copolímero de poli(ácido láctico-co-glicólico)-polietilenglicol-poli(ácido láctico-co-glicólico) (PLGAPEG-PLGA), o una mezcla de polímero de poli(ácido láctico-co-glicólico) (PLGA) y copolímero de poli(ácido láctico-co-glicólico)-polietilenglicol-poli(ácido láctico-co-glicólico) (PLGA-PEG-PLGA); (ii) con agitación, mezclar la emulsión obtenida de la etapa (i) con una solución acuosa de alcohol polivinílico (PVA); (iii) con agitación, agregar un solvente acuoso a la emulsión obtenida en la etapa (ii), donde dicho solvente acuoso es preferiblemente agua purificada; (iv) filtrar la emulsión obtenida de la etapa (iii); (v) liofilizar las partículas de polímero obtenidas en la etapa (iv); (vi) opcionalmente, esterilizar las partículas liofilizadas de polímero obtenidas en la etapa (v), preferiblemente con rayos gamma; y procedimiento para la preparación de composiciones farmacéuticas y/o cosméticas que comprenden dichas partículas.
ARP220101046A 2013-08-09 2022-04-22 Procedimiento para la preparación de partículas de polímero farmacéuticas y/o cosméticas, y procedimiento para la preparación de composiciones farmacéuticas y/o cosméticas que comprenden dichas partículas AR125407A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2013/066763 WO2015018461A1 (fr) 2013-08-09 2013-08-09 Compositions therapeutiques comprenant d'acide hyaluronique
PCT/IB2014/063744 WO2015019304A2 (fr) 2013-08-09 2014-08-06 Compositions à libération continue à base d'acide hyaluronique, et leurs applications thérapeutiques

Publications (1)

Publication Number Publication Date
AR125407A2 true AR125407A2 (es) 2023-07-12

Family

ID=49209321

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140104026A AR098201A1 (es) 2013-08-09 2014-10-27 Composiciones de liberación continua basadas sobre ácido hialurónico y aplicaciones terapéuticas de esas composiciones
ARP220101046A AR125407A2 (es) 2013-08-09 2022-04-22 Procedimiento para la preparación de partículas de polímero farmacéuticas y/o cosméticas, y procedimiento para la preparación de composiciones farmacéuticas y/o cosméticas que comprenden dichas partículas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140104026A AR098201A1 (es) 2013-08-09 2014-10-27 Composiciones de liberación continua basadas sobre ácido hialurónico y aplicaciones terapéuticas de esas composiciones

Country Status (9)

Country Link
US (3) US10842810B2 (es)
EP (1) EP3030225B1 (es)
CN (1) CN105744929B (es)
AR (2) AR098201A1 (es)
CA (1) CA2926169C (es)
ES (1) ES2835476T3 (es)
IL (1) IL243995B (es)
RU (1) RU2700593C2 (es)
WO (2) WO2015018461A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101637883B1 (ko) * 2015-09-30 2016-07-21 선바이오(주) 폴리에틸렌글리콜 수화젤 주사제
CN110423291B (zh) * 2019-09-06 2020-06-16 焦点生物医药有限公司 一种速溶透明质酸钠制备方法
AU2020400389B2 (en) * 2019-12-10 2024-02-15 Alcon Inc. Dissolvable polymeric eye inserts with a biodegradable polymer
FR3105729B1 (fr) 2019-12-31 2023-07-21 Mrs Biotech Composition pour la gestion du poids d’un sujet
CN113855849A (zh) * 2020-06-30 2021-12-31 孛朗孚(杭州)生物科技有限公司 一种敷料组合物及其制备方法和应用
WO2022045823A1 (ko) * 2020-08-31 2022-03-03 주식회사 바임 생분해성 고분자 분산체, 이를 포함하는 조성물 및 피부 개선용 시스템
CN115501390A (zh) * 2022-10-18 2022-12-23 沈阳药科大学 一种皮肤美容复合注射液及其制备方法
CN115970051B (zh) * 2023-02-09 2023-08-29 辽宁天贺生物科技研究院有限公司 可降解组织工程填充材料及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972906A (en) 1991-07-03 1999-10-26 Hyal Pharmaceutical Corporation Treatment of mucous membrane disease, trauma or condition and for the relief of pain thereof
IN181358B (es) 1995-02-14 1998-05-30 Bioniche Inc
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US6004573A (en) * 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
TW577758B (en) * 1997-10-27 2004-03-01 Ssp Co Ltd Intra-articular preparation for the treatment of arthropathy
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
KR20040065153A (ko) * 2001-11-14 2004-07-21 알자 코포레이션 주입가능한 데포 조성물
TW200307011A (en) * 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
WO2006002365A2 (en) 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
AU2005272578A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid and hyluronidase inhibitors
US20060140988A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Visco-supplement composition and methods
FR2909560B1 (fr) 2006-12-06 2012-12-28 Fabre Pierre Dermo Cosmetique Gel d'acide hyaluronique pour injection intradermique
WO2008147817A2 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Coated hyaluronic acid particles
UA111162C2 (uk) * 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
KR101304766B1 (ko) 2011-01-05 2013-09-05 서울대학교산학협력단 히알루론산을 포함하는 인공타액

Also Published As

Publication number Publication date
IL243995B (en) 2021-03-25
CA2926169C (fr) 2023-10-17
US20210023122A1 (en) 2021-01-28
EP3030225B1 (fr) 2020-09-02
RU2016105338A3 (es) 2018-06-07
RU2016105338A (ru) 2017-09-12
CA2926169A1 (fr) 2015-02-12
IL243995A0 (en) 2016-04-21
CN105744929A (zh) 2016-07-06
US10842810B2 (en) 2020-11-24
US20230190786A1 (en) 2023-06-22
ES2835476T3 (es) 2021-06-22
WO2015019304A3 (fr) 2015-04-23
CN105744929B (zh) 2021-09-28
US11738039B2 (en) 2023-08-29
WO2015018461A1 (fr) 2015-02-12
RU2700593C2 (ru) 2019-09-18
EP3030225A2 (fr) 2016-06-15
US20160175342A1 (en) 2016-06-23
WO2015019304A2 (fr) 2015-02-12
AR098201A1 (es) 2016-05-18

Similar Documents

Publication Publication Date Title
AR125407A2 (es) Procedimiento para la preparación de partículas de polímero farmacéuticas y/o cosméticas, y procedimiento para la preparación de composiciones farmacéuticas y/o cosméticas que comprenden dichas partículas
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
BR112012022223A8 (pt) Formulação de proteína concentrada, uso e método de preparação da mesma
BR112016028961A8 (pt) fibras eletrotorcidas, seu método de preparação e seu uso, bem como composição, e kit
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
BR112014032809A2 (pt) melhora de autofagia ou aumento de longevidade pela administração de urolitinas ou precursores das mesmas
ES2721325T3 (es) Método para producir de manera estéril partículas de lípido-ácido nucleico
BR112017013691A2 (pt) composição compreendendo um polímero em multiestágio, seu método de preparação e seu uso
BR112015021709A2 (pt) poli(beta-amino éster)es modificados para administração de fármacos
BR112015007231A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
AR102916A1 (es) Sistema de suministro nano particulado
EA201270050A1 (ru) Нанодисперсия лекарственного средства и способ ее получения
BR112016015701A2 (pt) Dendrímero de peptídeo, método de esterilização do mesmo, composição, composição farmacêutica, método de polimerização de fibrinogênio, kit para formação de um hidrogel e hidrogel
CL2018003178A1 (es) Composición farmacéutica
BR112018001978A2 (pt) composição farmacêutica compreendendo fibras obtidas de forma eletro-hidrodinâ¬mica, composição com tempo de permanência melhorado sobre o local de aplicação
NI201400122A (es) Agentes terapéuticos para administración subcutánea optimizados
BR112014011327A2 (pt) copolímeros em tribloco de estireno-siloxano como membranas para transporte seletivo de álcoois e outros compostos orgânicos em misturas aquosas
CO2019012814A2 (es) Composición farmacéutica líquida estable
EA201690005A1 (ru) Состав с модифицированной кинетикой высвобождения
BR112016002342A8 (pt) microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica
BR112014032583A8 (pt) forma farmacêutica para liberação prolongada de substâncias ativas e seu processo de produção